HGH 191AA Dosage: FDA Label Dose vs Common Research Practice
HGH 191AA dosage: the FDA label dose for approved somatropin, the IU-to-mg conversion, and common research-channel practice for comparison.
The short version
Two different numbers matter here. The FDA label dose is what a clinician uses for an approved somatropin product in a diagnosed patient: roughly 0.2 mg/day for adult growth hormone deficiency, titrated by labs. Separately, research-community sources describe common practice for a self-sourced HGH 191AA vial of roughly 1-4 IU (about 333 mcg-1.3 mg) once daily. Neither figure is a recommendation, and the second is not trial-established at all.
- FDA label dosing for adult growth hormone deficiency starts around 0.2 mg/day (0.15-0.3 mg/day), titrated by IGF-1 levels. It is not a fixed universal dose.
- 1 mg somatropin = 3 IU, per the FDA Omnitrope label's own cartridge-strength statement.
- Research-channel common practice for HGH 191AA runs roughly 1-4 IU/day. It is common practice, not FDA or trial-established dosing.
- Reconstitution and injection-volume arithmetic belongs on the dosage calculator, not a guess.
HGH 191AA is research-sold somatropin, the same molecule behind FDA-approved growth hormone drugs. This page gives both numbers that matter: the FDA label dose for an approved product, and what research-channel sources describe as common practice for a self-sourced vial. For what the molecule is and where it differs from the approved drugs, see the main guide.
US legal status - Research use only
Sold for laboratory research use only. Not approved by the FDA for human use, and cannot be lawfully marketed as a supplement or a medicine. Products sold this way are not made to pharmaceutical quality standards, and their contents are not verified by anyone.
The FDA label dose for approved somatropin
For adult growth hormone deficiency, FDA labels describe two approaches:
- Weight-based: a start of not more than 0.04 mg/kg/week, increased at 4-8 week intervals to not more than 0.08 mg/kg/week.
- Non-weight-based: “taking into account recent literature,” a start of about 0.2 mg/day (range 0.15-0.3 mg/day), increased gradually by roughly 0.1-0.2 mg/day according to clinical response and serum IGF-1.
Pediatric dosing is weight-based and depends on the indication. For pediatric GH deficiency, for example, it is 0.16-0.24 mg/kg/week, divided into 6-7 daily doses.
This is a prescriber’s starting point for a diagnosed patient on a specific approved formulation. It is not a fixed number, and not a self-directed dose.
The IU-to-mg conversion
The FDA’s Omnitrope label states cartridge strength in both units side by side: 5 mg/1.5 mL (15 IU) and 10 mg/1.5 mL (30 IU). That means 1 mg = 3 IU, or about 333 mcg per IU. The two units describe the same amount of somatropin, not different strengths.
This is not universal on every current US label. Norditropin’s label, for example, states dosing only in mg and mg/kg, with no IU figure printed anywhere on it.
HGH 191AA dosage: the common research-channel protocol
The protocol most often described for a research-sold HGH 191AA vial is roughly 1-4 IU (about 333 mcg-1.3 mg) by subcutaneous injection once daily. Cycles run 12-24 weeks, with a 4-8 week break. This is common practice compiled from research-chemical sources, not a dose established by any trial or the FDA for this product.
Common protocol
What is commonly used, not a dose established in trials. No regulator has set a dose for HGH 191AA. Sources differ, so the ranges below span them.
- Dose per administration
- 333-1333 mcg
- How often
- Once daily (split into a morning and evening dose above roughly 3 IU/day), subcutaneous
- Route
- Subcutaneous injection
- Cycle length
- 12-24 weeks
- Break between cycles
- 4-8 weeks
- Common vial size
- 5 mg
- Timing
- Fasted in the morning, or before bed; sources differ on which is more common. Injection sites rotated across abdomen, thigh and upper arm.
Sources describe common practice in IU; converted to mcg here using the FDA Omnitrope label's own strength statement (5 mg/1.5 mL = 15 IU, i.e. 1 mg = 3 IU = 333 mcg/IU), so 1-4 IU/day is roughly 333-1,333 mcg/day. This is the same molecule (somatropin) sold by prescription in FDA-approved products; the dose here is common research-channel practice for a self-sourced vial, not the FDA label's dose for its approved indications - see the FDA label dosing on the compound guide.
Plan a cycle in the protocol builder or work out injection volume in the dosage calculator.
The common HGH 191AA dose is 333-1333 mcg, Once daily (split into a morning and evening dose above roughly 3 IU/day), subcutaneous. From a 5 mg vial mixed with 2 mL of bacteriostatic water, 850 mcg is 34 units (0.34 mL) on a U-100 insulin syringe.
HGH 191AA 5 mg vial: units per dose
| Water added | Concentration | 1 unit = | 333 mcg | 850 mcg | 1.33 mg |
|---|---|---|---|---|---|
| 1 mL | 5 mg/mL | 50 mcg | 6.5 units | 17 units | 26.5 units |
| 2 mL | 2.5 mg/mL | 25 mcg | 13.5 units | 34 units | 53.5 units |
| 3 mL | 1.67 mg/mL | 16.67 mcg | 20 units | 51 units | 80 units |
All HGH 191AA vial sizes: 10 IU
Units are on a standard U-100 insulin syringe (100 units = 1 mL), rounded to the nearest half unit - half-unit marks are on 0.3 mL syringes. Water volumes are examples: more water means more units per dose, not more doses per vial. For any other vial or dose, use the calculator below.
How many 5 mg vials a cycle takes
| Scenario | Dose | Doses a week | Weeks | Total | 5 mg vials |
|---|---|---|---|---|---|
| Low end of the common protocol | 333 mcg | 7 | 12 | 27.97 mg | 6 |
| High end of the common protocol | 1.33 mg | 7 | 24 | 223.94 mg | 45 |
Whole vials, rounded up. Plan a cycle with your own numbers in the protocol builder. Keep mixed vials cold and use them within the window in how long reconstituted peptides last; where to inject: subcutaneous injection sites.
For reconstitution and injection-volume arithmetic, the dosage calculator performs the conversion. It does not choose a dose.
Who should not use it
No trial population exists for a self-sourced HGH 191AA vial to draw an exclusion list from. FDA labels for approved somatropin products list contraindications a prescriber screens for:
- acute critical illness
- active malignancy
- active proliferative or severe non-proliferative diabetic retinopathy
- closed epiphyses, in children
Anyone with a history of cancer, diabetes or active illness should not self-direct any growth-hormone product without a clinician who knows that history. A real or suspected growth hormone deficiency belongs with a prescriber and an approved product, not a research-channel vial.
HGH 191AA side effects and risks
Full detail is on the main guide. In short, FDA labels for approved products document:
- fluid retention
- joint pain
- carpal tunnel syndrome
- reduced insulin sensitivity and glucose intolerance
- tumor-related warnings for patients with a malignancy history
These are documented for a monitored, verified product. None of that monitoring applies to a self-sourced vial, which carries the additional, separate risk of unknown purity and unknown actual dose.
Related
- HGH 191AA: what it is and where approved somatropin fits
- MGF dosage
- CJC-1295 dosage
- Dosage calculator
HGH 191AA dosage calculator
Preset to a 5 mg vial and 333 mcg, the low end of the common protocol. Enter your own vial size, water and dose to get the syringe units to draw.
Your vial
Printed on the vial. There is no standard size - enter what yours says.
This changes how much you draw - never how many doses the vial holds.
100 units per mL. 1 unit = 0.01 mL. This is what almost every insulin syringe sold is, in every barrel size.
Capacity only. A 1 mL U-100 syringe holds 100 units - the scale decides that, not the barrel.
Draw this much
= 0.13 mL on a 1 mL U-100 syringe
- Concentration
- 2,500 mcg/mL
- Exact volume
- 0.1332 mL
- Dose you actually get(after rounding to the nearest mark)
- 325 mcg
- Doses per vial(unaffected by water volume)
- 15
Where to buy HGH 191AA for research
Each vendor is checked against my vendor checklist.
I don't list a vendor for HGH 191AA yet. Before buying from anyone, work through the vendor checklist.
Common questions
What is the FDA label dose for somatropin?
For adult growth hormone deficiency, FDA labels describe two approaches. One is a weight-based start, commonly not more than 0.04 mg/kg/week, titrated up to a maximum around 0.08 mg/kg/week. The other is a non-weight-based start of about 0.2 mg/day (range 0.15-0.3 mg/day), increased gradually by roughly 0.1-0.2 mg/day based on clinical response and IGF-1 levels. Pediatric dosing is weight-based and varies by indication. This is prescriber-managed dosing for a diagnosed patient on an approved product, not a number to self-apply.
How do I convert HGH IU to mg?
The FDA's Omnitrope label states cartridge strength in both units: 5 mg/1.5 mL (15 IU) and 10 mg/1.5 mL (30 IU). That puts the conversion at 1 mg = 3 IU, or about 333 mcg per IU. Not every somatropin label prints an IU figure. Norditropin's current label, for example, gives dosing only in mg and mg/kg.
What is the usual HGH 191AA research dose?
Research-channel sources put it at roughly 1-4 IU (about 333 mcg-1.3 mg) by subcutaneous injection once daily, in cycles of 12-24 weeks with a 4-8 week break. That is common practice compiled from research sources, not a dose any trial or the FDA has established for this product. See the protocol below for the sourcing.
Is there a difference between the FDA dose and the research-community dose?
Yes, and the number is only part of it. The FDA dose is for a diagnosed patient on a specific approved formulation, titrated by a clinician using lab results. The research-community figure is common practice for a self-sourced vial in people without a diagnosed condition. It is compiled from research-chemical and community sources, not a clinical trial or a regulator.
References (1 sources)
Bibliographic detail is fetched from PubMed, not written by me - so a citation here cannot drift from the paper it names. Study design comes from PubMed's own tags rather than my judgement.